2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2299

Acroosteolysis Is Associated with Increased Propensity for Osteoclast Formation and Higher VEGF Levels in the Peripheral Blood of Systemic Sclerosis Patients
Abstract Number: 2150

Action of Tofacitinib Via Human Dendritic Cells
Abstract Number: 2507

Activated Cullin-Ring Ubiquitin Ligases (CRLs) Dampen T Cell Signaling and Inactivation of Crls Arrests the Progression of Inflammatory Arthritis
Abstract Number: 2667

Activated Memory B Cell Compartment in Rheumatoid Arthritis: Impact of B Cell Depletion Therapy
Abstract Number: 902

Activation of NF-Kb Via Poly(I:C)-Induced Monocyte-Derived Microparticles Decreases TRAIL-Induced Apoptosis of Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1500

Activation of Pregnane X Receptor Induces Regression of Experimental Dermal Fibrosis
Abstract Number: 1497

Activation of Sirt1 Attenuates Bleomycin Induced Scleroderma Through Inhibiting Mammalian Target of Rapamycin Activation
Abstract Number: 25

Activation of the Canonical Wnt Signaling Pathway Is Tissue Dependent in Osteoarthritic Joints: Distinct Mechanisms of Regulation by Wnt Antagonists
Abstract Number: 689

Activation of the Interferon Pathway Is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients
Abstract Number: 479

Active Immunization with TNF-Kinoid in Rheumatoid Arthritis Patients with Secondary Resistance to Tumor Necrosis Factor-Alpha Antagonists Is Safe and Immunogenic
Abstract Number: 607

Activity Index After Renal Failure in a Cohort of 32 Patients with Lupus Nephritis
Abstract Number: 2446

Activity Limitations Experienced by People with Rheumatoid Arthritis On Biologic Medications and Their Use of Ergonomic Methods
Abstract Number: 1148

Adalimumab – Effective Control under Refractory JIA Associated Uveitis
Abstract Number: 5

Adalimumab Inhibits TNF-Enhanced Human Osteoclast Development More Effectively Than Other Biologic Agents Under in Vitro Conditions of Chronic TNF Exposure
Abstract Number: 1352

Adalimumab Significantly Reduces Recurrence Rate of Anterior Uveitis in Patients with Ankylosing Spondylitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].